

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:



Listing of Claims:


Claims 1-32 (cancelled).

Claim 33 (new): A method for treating a disease or condition in a mammal, wherein the disease or condition is caused by a genetic defect in a gene that mediates homologous recombination, the method comprising:

selecting the mammal having the genetic defect; and

administering to the mammal a compound selected from the group consisting of a compound of the formula I, formula II and formula III:





or a pharmaceutically acceptable salt thereof.

Claim 34(new): The method according to Claim 33, wherein the compound is the compound of the formula I.

Claim 35 (new): The method according to Claim 34, wherein the compound of the formula I is in the form of a phosphate salt.

Claim 36 (new): The method of Claim 33, wherein the disease is cancer.

Claim 37 (new): The method of Claim 36, wherein the cancer is breast cancer.

Claim 38 (new): The method of Claim 33, wherein the genetic defect is the absence of a gene encoding a protein involved in HR.

Claim 39 (new): The method of Claim 33, wherein the genetic defect is in the expression of a gene encoding a protein involved in HR.

Claim 40 (new): The method of Claim 33, wherein the gene that mediates homologous recombination is selected from the group consisting of XRCC1, ADPRT (PARP-1), ADPRTL2, (PARP02) CTPS, RPA, RPA1, RPA2, RPA3, XPD, ERCC1, XPF, MMS19, RAD51, RAD51 β , RAD51C, RAD51D, DMC1, XRCCR, XRCC3, BRCA1, BRCA2, RAD52, RAD54, RAD50, MRE11, NB51, WRN, BLM KU70, RU80, ATM, ATR CHK1, CHK2, FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, RAD1,

RAD9 and combinations thereof.




Claim 41 (new): The method of Claim 33, wherein the gene that mediates homologous recombination is a tumor suppressor gene.

Claim 42 (new): The method of Claim 41, wherein the tumor suppressor gene is BRCA1 and/or BRCA2.

Claim 43 (new): A method for inducing apoptosis of cells defective in a gene that mediates homologous recombination, the method comprising:

selecting the cells having the genetic defect; and

administering to the cells a compound selected from the group consisting of a compound of the formula I, formula II and formula III:



or a pharmaceutically acceptable salt thereof.

Claim 44 (new): The method according to Claim 43, wherein the compound is the compound of the formula I.

Claim 45 (new): The method according to Claim 44, wherein the compound of the formula I is in the form of a phosphate salt.

Claim 46 (new): The method of Claim 43 wherein the cells are cancer cells.

Claim 47 (new): The method of Claim 43, wherein the genetic defect of the cells is the absence of a gene encoding a protein involved in HR.

Claim 48 (new): The method of Claim 43, wherein the genetic defect of the cells is in the expression of a gene encoding a protein involved in HR.

Claim 49 (new): The method of Claim 43, wherein the gene that mediates homologous recombination is selected from the group consisting of XRCC1, ADPRT (PARP-1), ADPRTL2, (PARP02) CTPS, RPA, RPA1, RPA2, RPA3, XPD, ERCC1, XPF, MMS19, RAD51, RAD51 β , RAD51C, RAD51D, DMC1, XRCCR, XRCC3, BRCA1, BRCA2, RAD52, RAD54, RAD50, MRE11, NB51, WRN, BLM, KU70, KU80, ATM, ATR, CHK1, CHK2, FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, RAD1, RAD9 and combinations thereof.

Claim 50 (new): The method of Claim 43, wherein the gene that mediates homologous recombination is a tumor suppressor gene.

Claim 51 (new): The method of Claim 50, wherein the tumor suppressor gene is BRCA1 and/or BRCA2.